When was Attralus founded?

Attralus was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Attralus located?

Attralus is headquartered in San Francisco, United States. It is registered at 50 Francisco Street Suite 450, San Francisco, CA 94133, US.

How many employees does Attralus have?

As of Mar 31, 2026, the latest employee count at Attralus is 22.

Is Attralus a funded company?

Attralus is a funded company, having raised a total of $197M across 4 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Dec 27, 2019.

When was the latest funding round of Attralus?

Attralus' latest funding was a $***** Series B round on Feb 06, 2024, with participation from 7 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $2.11B in funding in 2026 to date.

Where does Attralus rank among its competitors?

Attralus ranks 5th amongst 46 active competitors, of which 27 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Primmune Therapeutics, which secured $8.6M in Jan, 2026.

Who are the top competitors of Attralus?

Attralus' top competitors include Inotrem, MAIA and Primmune Therapeutics. Among them, Primmune Therapeutics secured the most recent funding round in January, 2026.

Attralus - 2026 Company Profile, Team, Funding & Competitors

Attralus is a series B company based in San Francisco (United States), founded in 2019 by Jonathan Wall. It operates as a Developer of drugs for the treatment of Amyloid diseases. Attralus has raised $197M in funding from investors like VenBio, Logos and Alpha Wave Global. The company has 46 active competitors, including 27 funded and 6 that have exited. Its top competitors include companies like Inotrem, MAIA and Primmune Therapeutics.

Company Details

Developer of drugs for the treatment of Amyloid diseases. The lead product AT-01 uses a polybasic peptide radiotracer technology and helps in the diagnostic of amyloid diseases. Other products include AT-02 & AT-03 which are PAR-SAP components that mediate binding to all types of amyloid and the Fc stimulates the immune system to remove amyloid.

Website: attralus.com
Social
Phone Number: +1 **********
Registered Address: 50 Francisco Street Suite 450, San Francisco, CA 94133, US

Key Metrics

Founded Year

2019

Location

San Francisco, United States

Stage

Series B

Total Funding

$197M in 4 rounds

Latest Funding Round

Series B, Feb 06, 2024, $*****

Investors

VenBio & 14 more

Ranked

5^th among 46 active competitors

Employee Count

22 as on Mar 31, 2026

Similar Companies

Inotrem & 58 more

View Attralus' full profile

Attralus is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Attralus, Inc. CIN: 20231019151 , United States, Active	Jan 04, 2023	-	-	-

Attralus has raised a total funding of $197M over 4 rounds. Its first funding round was on Dec 27, 2019. Its latest funding round was a Series B round on Feb 06, 2024 for $*****. 7 investors participated in its latest round. Attralus has 15 institutional investors.

Here is the list of recent funding rounds of Attralus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 06, 2024	7386841	Series B	3683506	1184563	6300802	2354540
Sep 08, 2021	1944293	Series B	2455830	3937010	7734988	VenBio & 6 more
Sep 14, 2020	6035182	Series A	4479064	3923493	VenBio	3316921

Access funding benchmarks and valuations. Sign up today!

View details of Attralus's funding rounds and investors

The founders of Attralus is Jonathan Wall.

Here are the details of Attralus' key team members:

Jonathan Wall: Co-Founder of Attralus.
Contact Info: 1 email address

View details of Attralus's Founder profiles and Board Members

Attralus' employee count trend

Attralus has 22 employees as of Mar 26. Here is Attralus's employee count trend over the years:

Uncover Attralus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Attralus include Inotrem, MAIA and Primmune Therapeutics. Here is the list of Top 10 competitors of Attralus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Inotrem 2013, Paris (France), Series B	Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction	$122M	Morningside, Edmond de Rothschild & 11 others	63/100
2nd	MAIA 2018, Chicago (United States), Public	Developer of immunotherapeutic solutions for cancer treatment	$8M	Checkmate Capital, BRK Financial Group & 1 others	62/100
3rd	Primmune Therapeutics 2017, San Diego (United States), Series B	Developer of immunotherapies for treating cancer	$60M	CAM Capital, BioRock Ventures & 8 others	60/100
4th	Actym Therapeutics 2017, Berkeley (United States), Series A	Developer of immunotherapy solutions for cancer and other serious diseases	$59.5M	Boehringer Ingelheim Venture Fund, Illumina Ventures ... & 4 others	57/100
5th	Attralus 2019, San Francisco (United States), Series B	Developer of drugs for the treatment of Amyloid diseases	$197M	Logos, Citadel & 13 others	57/100
6th	Bright Peak Therapeutics 2017, Basel (Switzerland), Series C	Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease	$232M	RA Capital Management, Versant Ventures & 9 others	56/100
7th	NodThera 2016, Duxford (United Kingdom), Series B	Developer of therapeutics for treating inflammatory and neuroinflammatory diseases	$95M	5AM Ventures, Novo Holdings & 6 others	56/100
8th	DEM BioPharma 2022, Cambridge (United States), Seed	Developer of immunotherapeutics for the treatment of cancer	$70M	Longwood Fund, Alta Partners & 7 others	56/100
9th	Metrio Pharm 2007, Richterswil (Switzerland), Public	Clinical stage Biopharma developing small molecule immune modulator against chronic immune disorders	$49.8M	Germany Trade & Invest, Europa	56/100
10th	Pheast 2020, Palo Alto (United States), Series C	Developer of immunotherapeutics for cancer treatment	$101M	Alexandria, Arch Venture Partners & 2 others	56/100